PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Boniolo, F ; Dorigatti, E. ; Ohnmacht, A. ; Saur, D.* ; Schubert, B. ; Menden, M.P.

Artificial intelligence in early drug discovery enabling precision medicine.

Expert Opin. Drug Discov. 16, 991-1007 (2021)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Introduction: Precision medicine is the concept of treating diseases based on environmental factors, lifestyles, and molecular profiles of patients. This approach has been found to increase success rates of clinical trials and accelerate drug approvals. However, current precision medicine applications in early drug discovery use only a handful of molecular biomarkers to make decisions, whilst clinics gear up to capture the full molecular landscape of patients in the near future. This deep multi-omics characterization demands new analysis strategies to identify appropriate treatment regimens, which we envision will be pioneered by artificial intelligence.Areas covered: In this review, the authors discuss the current state of drug discovery in precision medicine and present our vision of how artificial intelligence will impact biomarker discovery and drug design.Expert opinion: Precision medicine is expected to revolutionize modern medicine; however, its traditional form is focusing on a few biomarkers, thus not equipped to leverage the full power of molecular landscapes. For learning how the development of drugs can be tailored to the heterogeneity of patients across their molecular profiles, artificial intelligence algorithms are the next frontier in precision medicine and will enable a fully personalized approach in drug design, and thus ultimately impacting clinical practice.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.098
1.450
3
10
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Artificial Intelligence ; Biomarker Discovery ; Deep Learning ; Drug Repurposing ; Machine Learning ; Patient Stratification ; Precision Medicine ; Protein Design ; Small Molecule Design ; Vaccine Design; Epitope Vaccine Design; Deep Learning Approach; Mhc Class-i; Neural-networks; Lung-cancer; Cell-lines; Big Data; Prediction; Tumor; Generation
Language english
Publication Year 2021
HGF-reported in Year 2021
ISSN (print) / ISBN 1746-0441
e-ISSN 1746-045X
Journal Expert Opinion on Drug Discovery
Quellenangaben Volume: 16, Issue: 9, Pages: 991-1007 Article Number: , Supplement: ,
Publisher Informa Healthcare
Publishing Place London
Reviewing status Peer reviewed
Institute(s) Institute of Computational Biology (ICB)
POF-Topic(s) 30205 - Bioengineering and Digital Health
Research field(s) Enabling and Novel Technologies
PSP Element(s) G-554700-001
G-503800-001
Grants Postdoctoral Fellowship Program of the Helmholtz Zentrum Muenchen
Munich School for Data Science (MuDS, from the Helmholtz Association)
European Research Council (ERC) under the European Union
DOI 10.1080/17460441.2021.1918096
WOS ID WOS:000657250100001
Scopus ID 85107505118
PubMed ID 34075855
Erfassungsdatum 2021-07-06
[➜Report correction]